Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First human use for Orbus' bio-engineered stent:

This article was originally published in Clinica

Executive Summary

The first human implant of Orbus Medical Technologies' bio-engineered coronary stent for preventing restenosis took place last week. The coronary R stent incorporates a bio-engineered surface, called Genous, which uses antibodies to capture the patient's own circulating endothelial progenitor cells (EPCs) and recruit them to the stent's surface (see Clinica No 1028, p 19). After rapidly covering the surface, the EPCs differentiate into mature endothelial cells, and within hours provide an effective barrier against the processes that can initiate restenosis, says the Fort Lauderdale, Florida firm. The technology may also have use in peripheral stents, artificial grafts and heart valves.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT062369

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel